logo
Menu

We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Drugs > Pembrolizumab in addition to chemotherapy for locally recurrent, inoperable or metastatic triple-negative breast cancer – first line

< Back

Pembrolizumab in addition to chemotherapy for locally recurrent, inoperable or metastatic triple-negative breast cancer – first line

Drugs

Cancer and Palliative Care

September 2018


Pembrolizumab, in addition to chemotherapy, is in clinical development for adults with triple-negative breast cancer (TNBC) that is locally recurrent, inoperable or metastatic. TNBC is an uncommon type of breast cancer whose cells do not have receptors for the hormones oestrogen and progesterone or HER2 protein. This means that many cancer treatments do not work for people with TNBC. Patients with TNBC have worse clinical outcomes and a unique pattern of recurrence compared with the other major subtypes of breast cancer. Patients with TNBC have been shown to have the highest rate of recurrence within the first 5 years after diagnosis.
Pembrolizumab is a drug administered by intravenous infusion which stimulates the body’s own immune system to fight cancer cells. If licensed, pembrolizumab in addition to chemotherapy could provide an alternative first line treatment option to patients who currently have limited treatment options for locally recurrent or metastatic TNBC not previously treated with chemotherapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts